The SC21 Bio-Pharma Laboratories, designed to meet the highest standards for pharmaceutical production, focuses on the development and manufacturing of next-generation stem cell and immunotherapy treatments. The THAI FDA licensing solidifies the facility’s commitment to quality and compliance, allowing it to manufacture therapeutic-grade products that meet stringent regulatory requirements. The laboratory will drive advancements in the treatment of degenerative and chronic diseases, covering therapeutic areas including oncology, neurology, metabolic disorders, and age-related conditions.

“Securing THAI FDA licensing for our new SC21 Bio-Pharma Laboratories represents our dedication to providing safe, high-quality cell-based therapeutics for clinical trial programs,” said the CEO of StemCells21. “Our facility is equipped with advanced technologies to manufacture innovative therapies, with the goal of making cell therapy more accessible to patients both regionally and globally.”

The THAI FDA-licensed manufacturing laboratories include specialized clean rooms, high-end cell processing equipment, and rigorous quality control systems to ensure the production of safe, high-quality therapies. The facility’s licensure empowers SC21 Bio-Pharma Laboratories to operate at the forefront of bio-pharmaceutical production in Asia, producing cell-based products and laying the foundation for expanding cell therapy applications worldwide.

StemCells21 envisions SC21 Bio-Pharma Laboratories as a hub for groundbreaking biopharma research, with plans to collaborate with leading global biotech organizations. This collaboration aims to accelerate the development of regenerative treatments and improve access to novel therapies.

With this launch, StemCells21’s SC21 Bio-Pharma Laboratories not only positions Thailand as a key player in the bio-pharma industry but also sets new standards for quality and innovation in Asia’s healthcare landscape.

For more information visit: www.sc21.com